anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The December 2019 outbreak of COVID-19 has now evolved into a public health emergency of global concern. Given the rapid spread of infection, the rapid depletion of hospital resources due to high influxes of patients, and the current absence of specific therapeutic drugs and vaccines for treatment of COVID-19 infection, it is essential to detect onset of the disease at its early stages. Radiological examinations, the most common of which are posteroanterior chest X-ray (PCX) images, play an important role in the diagnosis of COVID-19. The objective of this study is to assess three configurations of two convolutional deep neural network architectures for the classification of COVID-19 PCX images. The primary experimental dataset consisted of 115 COVID-19 positive and 115 COVID-19 negative PCX images, the latter comprising roughly equally many pneumonia, emphysema, fibrosis, and healthy images (230 total images). Two common convolutional neural network architectures were used, VGG16 and DenseNet121, the former initially configured with off-the-shelf (OTS) parameters and the latter with either OTS or exclusively X-ray trained (XRT) parameters. The OTS parameters were derived from training on the ImageNet dataset, while the XRT parameters were obtained from training on the NIH chest X-ray dataset, ChestX-ray14. A final, densely connected layer was added to each model, the parameters of which were trained and validated on 87% of images from the experimental dataset, for the task of binary classification of images as COVID-19 positive or COVID-19 negative. Each model was tested on a hold-out set consisting of the other 13% of images. Performance metrics were calculated as the average over five random 80%-20% splits of the images into training and validation sets, respectively.
Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
Around 60% of individuals with neurodevelopmental disorders (NDD) remain undiagnosed after comprehensive genetic testing, primarily of protein-coding genes1. Large genome-sequenced cohorts are improving our ability to discover new diagnoses in the non-coding genome. Here we identify the non-coding RNA RNU4-2 as a syndromic NDD gene. RNU4-2 encodes the U4 small nuclear RNA (snRNA), which is a critical component of the U4/U6.U5 tri-snRNP complex of the major spliceosome2. We identify an 18 base pair region of RNU4-2 mapping to two structural elements in the U4/U6 snRNA duplex (the T-loop and stem III) that is severely depleted of variation in the general population, but in which we identify heterozygous variants in 115 individuals with NDD. Most individuals (77.4%) have the same highly recurrent single base insertion (n.64_65insT). In 54 individuals in whom it could be determined, the de novo variants were all on the maternal allele. We demonstrate that RNU4-2 is highly expressed in the developing human brain, in contrast to RNU4-1 and other U4 homologues. Using RNA sequencing, we show how 5' splice-site use is systematically disrupted in individuals with RNU4-2 variants, consistent with the known role of this region during spliceosome activation. Finally, we estimate that variants in this 18 base pair region explain 0.4% of individuals with NDD. This work underscores the importance of non-coding genes in rare disorders and will provide a diagnosis to thousands of individuals with NDD worldwide.
Background: Sprains constitute most of ankle injury and 85% ankle sprain is inversion injury. The conventional treatment includes medication, physical therapy, bracing and steroid injection. Anterior talofibular ligament is the most injured ligament in ankle sprain. Although the response of acute ligament sprain is usually quickly, treatment of chronic ligament sprain is difficult. Chronic pain and ankle instability is the most common symptom in chronic ankle sprain. Dextrose prolotherapies been used for treating soft tissue injury such as osteoarthritis, tendinopathy and ligament sprain. However, there is not randomized control trial for hypertonic dextrose injection to chronic ankle sprain.

Methods: Investigators will include 40 ankle sprain patients who have ankle pain or instability sensation more than 3 months. Ultrasonography will be done for confirm ligament injury. Participants will be randomized into two groups. Dextrose injection group will accept dextrose 15% injection to tendon and enthesis. Otherwise, investigators will do subcutaneous sham injection to control group. Investigators will measure pain threshold and peak pressure by algometer, the degree of ankle instability by ultrasound, the proprioception by single leg standing, and foot and ankle questionnaire. The examination will be done before injection, immediately after injection, 1 week, 4 weeks and 12 weeks after injection.To our hypothesis, investigators suggest dextrose prolotherapy injection could decrease pain and improved proprioception.
Novel means have been discovered for increasing the resistance of a mammalian host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by 'arming' the host's cells with a gene encoding the lytic peptide cecropin B. The host's own leukocytes, other cells involved in resistance to infection, or other cells are transformed, and expression of the gene is induced when needed to combat pathogens. Transfection of hematopoietic stem cells with the cecropin B gene will enhance disease resistance in mammals; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. The transformed cells have the ability to produce and secrete a broad spectrum chemotherapeutic agent which has a systemic effect on certain pathogens, particularly pathogens that might otherwise evade or overcome host defenses. The peptide's expression preferably induced only in areas of infection, where it will most effectively augment the host's defense systems. Expression of the exogenous gene does not damage a healthy recipient cell.
BACKGROUND: The US Public Health Service (USPHS) designated tobacco dependence as a chronic disease. This is especially true for smokers with serious mental illness (SMI) who make more cessation attempts and are less successful sustaining long-term abstinence than the general population. There is a significant health disparity wherein individuals with SMI have a higher tobacco use prevalence and a greater risk for tobacco-related mortality than the general population. Chronic care models suggest chronic disease management requires a multidisciplinary care team to assess tobacco use, administer treatment, support patient self-management, and monitor progress. Proactive telephone outreach to smokers and brief provider interventions are two effective chronic disease management strategies. Community based mental health centers (CMHCs) are a primary treatment access point for many smokers with SMI. However, rates of intervention with smoking by CMHC providers are low. In order to implement the chronic care model for tobacco dependence for CMHCs, comprehensive implementation strategies are needed. OBJECTIVE: to conduct a feasibility pilot trial to adapt an implementation strategy developed by the SAMHSA-funded network of Addiction Technology Transfer Centers (ATTCs) to integrate a proactive, chronic care model of tobacco cessation treatment into CMHCs. AIM: To conduct a pilot trial to assess the feasibility, acceptability and initial effectiveness of the implementation strategy. DESIGN: The investigators will conduct a pilot hybrid type 2 implementation-effectiveness trial in 3 CMHCs (N=50 patients; 96-130 providers). The investigators will conduct 2 baseline assessments (3 months apart) and outcomes will be assessed at 3, 6, and 12-months post implementation.

Outcomes include feasibility, acceptability, effectiveness of the implementation strategy on tobacco cessation treatment utilization (counseling and medication) and patient effectiveness on tobacco cessation (CO confirmed 7-day point prevalence abstinence). SIGNIFICANCE: An effective implementation strategy for tobacco cessation treatment in CMHCs, a widespread model of care delivery, would have enormous public health impact.
Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
The movement toward prevention trials in people at-risk for Parkinson's disease (PD) is rapidly becoming a reality. The authors of this article include a genetically at-risk advocate with the LRRK2 G2019 S variant and two patients with rapid eye movement sleep behavior disorder (RBD), one of whom has now been diagnosed with PD. These authors participated as speakers, panelists, and moderators in the "Planning for Prevention of Parkinson's: A Trial Design Forum" hosted by Massachusetts General Hospital in 2021 and 2022. Other authors include a young onset person with Parkinson's (PwP) and retired family physician, an expert in patient engagement in Parkinson's, and early career and veteran movement disorders clinician researchers. Several themes emerged from the at-risk participant voice concerning the importance of early intervention, the legitimacy of their input in decision-making, and the desire for transparent communication and feedback throughout the entire research study process. Challenges and opportunities in the current environment include lack of awareness among primary care physicians and general neurologists about PD risk, legal and psychological implications of risk disclosure, limited return of individual research study results, and undefined engagement and integration of individuals at-risk into the broader Parkinson's community. Incorporating the perspectives of individuals at-risk as well as those living with PD at this early stage of prevention trial development is crucial to success.
Alginate-based materials present promising potential for emergency hemostasis due to their excellent properties, such as procoagulant capability, biocompatibility, low immunogenicity, and cost-effectiveness. However, the inherent deficiencies in water solubility and mechanical strength pose a threat to hemostatic efficiency. Here, we innovatively developed a macromolecular cross-linked alginate aerogel based on norbornene- and thiol-functionalized alginates through a combined thiol-ene cross-linking/freeze-drying process. The resulting aerogel features an interconnected macroporous structure with remarkable water-uptake capacity (approximately 9000 % in weight ratio), contributing to efficient blood absorption, while the enhanced mechanical strength of the aerogel ensures stability and durability during the hemostatic process. Comprehensive hemostasis-relevant assays demonstrated that the aerogel possessed outstanding coagulation capability, which is attributed to the synergistic impacts on concentrating effect, platelet enrichment, and intrinsic coagulation pathway. Upon application to in vivo uncontrolled hemorrhage models of tail amputation and hepatic injury, the aerogel demonstrated significantly superior performance compared to commercial alginate hemostatic agent, yielding reductions in clotting time and blood loss of up to 80 % and 85 %, respectively. Collectively, our work illustrated that the alginate porous aerogel overcomes the deficiencies of alginate materials while exhibiting exceptional performance in hemorrhage, rendering it an appealing candidate for rapid hemostasis.
Purpose: This study investigated acute workload (wAW), chronic workload (wCW), acute: chronic workload ratio (wACWR), training monotony (wTM), perceived load training strain indicators (wTS), and countermove- ment jump (CMJ) as indicators of wellness in one season and defined weekly variations. In addition, we analyzed the relationships between training load measurements and weekly reports. Methods: 16 elite young wrestlers were monitored daily with individual observations for 46 consecutive weeks throughout the season. Training load was obtained using the session rating of perceived effort. wSleep, wStress, wFatigue & wMuscle Soreness well-being were monitored daily using the Hooper index. Results: As a result of the analysis, it was found that there is a moderate relationship (r = 0.51, p = .003) between ACWR and w mean load (A.U.) and a high relationship (r = 0.81, p < .001) between monotony and strain. Conclusion: All variables other than ACWR, w mean load, strain, and monotony presented small and statistically insignificant relationships. These results provide coaches and practitioners with new insights into perceived loads and health changes during a season at the elite youth level.
A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.
Preparation and application of a pure natural compound essential oil having broad-spectrum bactericidal activity. The compound essential oil is obtained by extracting volatile oils from dry roots and stems of Atractylodes lancea (Thunb.) DC. or Atractylodes chinensis (DC.) Koidz. which belong to atractylodes plants of the Compositae family as well as dry twigs or bark of cinnamonum cassia Presl. which belongs to Lauraceae plants, and then mixing and compounding the volatile oils, the volume content of the two volatile oils being: 40-70 parts atractylode volatile oil and 30-60 parts of cassia twig volatile oil. The compound essential oil may have a strong killing effect on Staphylococcus aureus, Escherichia coli and Candida albicans.
After the primary outcome assessment at 12 weeks, control group participants will be offered HOW R U? intervention support outside of the main trial. They will be allowed to choose either intergenerational or same-generation versions.
During cancer cell invasion, integrin undergoes constant endo/exocytic trafficking. It has been found that the recycling ability of integrin β1 through Rab11-controlled long loop pathways is directly associated with cancer invasion. Previous studies showed that gain-of-function mutant p53 regulates the Rab-coupling protein [RCP]-mediated integrin β1 recycling by inactivating tumor suppressor TAp63. So, we were interested to investigate the involvement of miR-205 in this process. In the current study first, we evaluated that the lower expression of miR-205 in MDA-MB-231 cell line is associated with high motility and invasiveness. Further investigation corroborated that miR-205 directly targets RCP resulting in attenuated RCP-mediated integrin β1 recycling. Overexpression of TAp63 validates our in vitro findings. To appraise the anti-metastatic role of miR-205, we developed two in vivo experimental models- xenograft-chick embryo and xenograft-immunosuppressed BALB/c mice. Our in vivo results support the negative effect of miR-205 on metastasis. Therefore, these findings advocate the tumor suppressor activity of miR-205 in breast cancer cells and suggest that in the future development of miR-205-targeting RNAi therapeutics could be a smart alternative approach to prevent the metastatic fate of the disease.
Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
Adenosine is an effective vasodilator used in SPECT-Myocardial Perfusion Imaging (SPECT-MPI). However, it produces transient symptoms that are poorly tolerated by most subjects. PGxHealth has designed a multi-center, randomized crossover, double-blind study to compare the safety and effectiveness of apadenoson to adenosine (Adenoscan®) in SPECT-MPI. Subjects who are clinical candidates for SPECT-MPI will be enrolled to undergo two sequential SPECT-MPI studies. The first study will use adenosine as the stress agent in approximately 1300 subjects. Eligible subjects will then be randomized in a 1:2 assignment ratio to receive a second SPECT-MPI using either adenosine or apadenoson as the pharmacologic stress agent, with the goal of obtaining a total of 753 subjects who complete both studies. The similarity of the results from the two adenosine:adenosine stress tests will be compared to those from the adenosine:apadenoson tests to assess efficacy. The incidence and intensity of commonly reported side effects will be compared to evaluate improved tolerability.
Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms (see PRECAUTIONS). Mild or moderate hypoglycemia occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients.

The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU).
Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m\^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
PURPOSE:An oral cavity composition containing an inorganic acid salt of chitosan as a binder, having physical stability, reducing astrigency caused by silica when it is used as an abrading agent, having also preventive action on alveolaris. CONSTITUTION:An oral cavity composition containing an inorganic acid salt or organic acid salt (chitosan salt) of chitosan as a binder. Since the chitosan salt has stable binding ability and its aqueous solution is acidic, it is advantageous for a drug component and an abrading agent stable in an acidic side. Although toothpaste using silica as an abrading agent shows astringency, the astringency can be eliminated by adding the chitosan salt to it without treating it by a specific means. Mouthwash, refreshing agent in the mouth, chewing gum, etc. including toothpaste may be cited as a oral cavity composition. An amount of the chitosan salt blended is 0.5-5wt% in tooth paste, and an amount of a drug component for preventing pyorrhea alveolaris is about 0.01wt%.
FIELD: biotechnology; medicine; agriculture.SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Disclosed is a gene-therapeutic DNA vector based on a gene-therapeutic DNA vector VTvaf17, carrying a target gene selected from a group of SHH, CTNNB1, NOG, WNT7A genes, to increase the level of expression of this target gene in the human and animal body. Gene-therapeutic DNA vector VTvaf17-SHH, or VTvaf17-CTNNB1, or VTvaf17-NOG, or VTvaf17-WNT7A, has a nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. Invention also discloses a method of producing said vector, use of a vector, an Escherichia coli strain carrying said vector, as well as a method of producing said vector on an industrial scale.EFFECT: invention can be used for safe application for human and animal genetic therapy.14 cl, 20 ex, 15 dwg
PURPOSE:To provide the titled composition containing a non-steroidal anti-inflammatory analgesic, its salt, or their derivative, and a nicotinic acid ester, and having excellent transcutaneous absorbability. CONSTITUTION:The objective anti-inflammatory analgesic drug for external use having excellent transcutaneous absorbability can be prepared by compounding (A) 100pts.wt. of a non-steroidal anti-inflammatory analgesic (exclusing salicyclic acid derivative, diclofenac and indomethacin: e.g. phenylacetic acid derivative such as alkofenac, indoleacetic acid derivative such as sulindac, propionic acid derivative such as ibuprofen, anthranylic acid derivative such as flufenamic acid, pyrazolone derivative such as phenylbutazone, oxicam-type acidic agent such as pyroxicam, or non-acidic agent such as tinoridine) with (B) >=5pts.wt., preferably >=10pts.wt. of a nicotinic acid ester. In the case of the treatment of the pain of shoulder discomfort, rheumatism, etc., it is applied continuously for 1-2 weeks at a dose of 1g/dose, and 3-4 doses daily.
<P>PROBLEM TO BE SOLVED: To provide an immunomodulator containing an immunoglobulin derived from milk and blood of mammal, an immunoglobulin derived from egg and blood of domestic fowls and their enzyme treated materials as active ingredients.  <P>SOLUTION: The immunomodulator comprises at least one kind of substance selected from the immunomodulator containing the immunoglobulin derived from milk and blood of mammal, the immunoglobulin derived from egg and blood of domestic fowls and their enzyme treated materials as an active ingredient. The immunomodulator comprises, preferably, the immunoglobulin derived from milk of mammal and/or its enzyme treated material as the active ingredient. The enzyme treated material comprises, preferably, Fab fragment and/or Fc fragment of the immunoglobulin derived from milk of mammal and/or the immunoglobulin derived from egg of domestic fowls. The immunomodulator promotes expression of cytokine and promotes production of the immunoglobulin by orally ingesting the immunomodulator. Thereby, immunomodulating effect can be expected.  <P>COPYRIGHT: (C)2005,JPO&NCIPI